<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5565">
  <stage>Registered</stage>
  <submitdate>30/08/2010</submitdate>
  <approvaldate>30/08/2010</approvaldate>
  <nctid>NCT01191996</nctid>
  <trial_identification>
    <studytitle>Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis</studytitle>
    <scientifictitle>A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MIS416-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Secondary Progressive Multiple Sclerosis</healthcondition>
    <healthcondition>Primary Progressive Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - MIS416

Experimental: MIS416 - MIS416, immunomodulating microparticle, given intravenously weekly


Other interventions: MIS416
MIS416 intravenously every week

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety profile, including maximum tolerated dose - Dose-limiting toxicities, adverse events, safety MRI assessments</outcome>
      <timepoint>1 month in DE phase, 3 months in DC phase</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamic assessments - Serum and cellular immunological assays</outcome>
      <timepoint>1 month in DE phase, 3 months in DC phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>MRI assessments - Safety MRIs</outcome>
      <timepoint>1 month in DE phase, 3 months in DC phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical status - Neurological examination, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), Fatigue Severity Scale (FSS), Multiple Sclerosis Quality of Life (MSQLI).</outcome>
      <timepoint>3 months in DC phase</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age.

          -  Diagnosis of MS, by the McDonald criteria.

          -  Chronic progressive MS (CPMS), defined as either primary progressive MS (PPMS) or
             secondary progressive MS (SPMS), per the criteria of the National Multiple Sclerosis
             Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple
             Sclerosis. [NOTE: In the dose-confirmation phase, only subjects with SPMS may be
             enrolled].

          -  MS is clinically active with worsening clinical status within the past 2 years,
             defined as an increase in EDSS by 1 point or more, sustained for at least 6 months.

          -  Expanded Disability Status Scale (EDSS) of 2.5 to 7.0 at Screening.

          -  The following laboratory values must be documented within 3 days prior to initiation
             of study drug:

               -  Absolute neutrophil count (ANC) &gt;= 1 x 109/L

               -  Platelet count &gt;= 100 x 109/L

               -  Serum creatinine =&lt; 1.5 mg/dL

               -  AST (SGOT) and ALT (SGPT) =&lt; 2 × upper limit of normal.

          -  Provide written informed consent to participate.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Relapsing-remitting MS or progressive-relapsing MS

          -  Any immunomodulatory drug therapy or immunosuppressive therapy within the previous six
             months, or vaccine or systemic corticosteroids within the previous 60 days, prior to
             initiation of study drug.

          -  Exposure to other experimental treatments currently under investigation in MS clinical
             trials, including alemtuzamab, rituximab, fingolimod, and clabribine.

          -  A diagnosis or history of collagen vascular disease (including Sjögren's syndrome and
             systemic lupus erythematosus), anticardiolipin antibody syndrome, cerebral autosomal
             dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL),
             sarcoidosis, vasculitis, Bechet's syndrome and/or Lyme disease.

          -  History of alcohol or drug abuse (with the exception of cannabinoids) within 2 years
             prior to initiation of study drug.

          -  Previous exposure to MIS416.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Innate Immunotherapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Primorus Clinical Trials</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Multiple Sclerosis Society</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine the safety and tolerability, dose-limiting
      toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously
      administered MIS416 weekly in patients with chronic progressive multiple sclerosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01191996</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alison Luckey</name>
      <address>Primorus Clinical Trials</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>